Brief: Cutia Therapeutics Says Abbreviated New Drug Application For CU-40105 Accepted By NMPA China
19/11/2025 01:16
Nov 19 (Reuters) - Cutia Therapeutics 2487.HK: ABBREVIATED NEW DRUG APPLICATION FOR CU-40105 SELF-DEVELOPED TOPICAL FINASTERIDE SPRAY ACCEPTED BY NMPA CHINA Further company coverage: 2487.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cutia Therapeutics
See all newsBrief: Cutia Therapeutics To Implement Share Repurchase Program From Oct 2 To Dec 31
Brief: Cutia Therapeutics Says Cu-40102 Bags Marketing Approval From Macao Pharmaceutical Administration Bureau
Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
Brief: Cutia Therapeutics Posts HY Loss Of RMB180.4 MLN
Brief: Cutia Therapeutics Says CU-30101 Obtains Drug Marketing Authorization By NMPA China